Paper Details

  1. Home
  2. Paper Details

Innovative tumour targeting therapeutics in Cushing's disease.

Author: TheodoropoulouMarily, von SelzamVivian

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This review discusses pharmacological treatment options for Cushing's disease (CD), a frequent form of endogenous hypercortisolism. While pituitary surgery remains the mainstay treatment, the review highlights the limitations of current pharmacotherapies, particularly dopamine agonists and somatostatin analogues, which often have low efficacy and substantial side effects. The review explores potential new targets and compounds for treating CD based on recent discoveries in the genetics and pathophysiology of corticotroph tumorigenesis.
Paper Details　
Original Abstract of the Article :
Cushing's disease (CD) is the most frequent form of endogenous hypercortisolism. Management of this devastating condition relies on pituitary surgery, while effective pharmacological treatment mainly focus on periphery targeting pharmaceuticals. Approved tumour-targeting drugs are limited to dopamin...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.beem.2022.101701

データ提供：米国国立医学図書館（NLM）

New Therapeutic Targets for Cushing's Disease: A Journey Through the Desert of Endocrine Disorders

Cushing’s disease (CD), a condition characterized by excessive cortisol production, presents a significant challenge for medical professionals. This study explores innovative therapeutic targets for CD, focusing on tumor-targeting approaches. The authors highlight the limitations of current treatments, including pituitary surgery and dopamine agonists, which often have limited efficacy and substantial side effects. They discuss promising preclinical studies on retinoic acid and other potential targets, such as silibinin, gefitinib, and roscovitine, which show promise but require further clinical evaluation for safety and efficacy.

The Quest for Effective CD Treatments: A Desert Oasis of Hope

The study underscores the need for new and effective treatments for CD. Imagine the vast desert landscape, a challenging environment where life must adapt to thrive. Similarly, CD presents a complex and challenging condition that requires innovative approaches to treat. This study, like a desert oasis, offers hope for a better future for patients with CD by exploring new therapeutic targets and avenues for research.

A Holistic Approach to CD Care

The study emphasizes the need for a multifaceted approach to CD care. It highlights the importance of exploring new therapeutic targets and developing treatments that specifically target the tumor cells. Just as a camel navigates the desert using its unique adaptations, researchers must utilize a holistic approach to understand and treat CD, considering various aspects of the disease and exploring new frontiers in medicine.

Dr.Camel's Conclusion

This study, like a desert caravan, reminds us that the journey towards better treatments for CD is ongoing. It's a testament to the tireless efforts of researchers who are constantly seeking new and effective ways to manage this challenging condition. The pursuit of new therapeutic targets for CD is a journey of hope and progress, where the ultimate goal is to improve the lives of those affected by this disease.

Date :
  1. Date Completed 2022-12-29
  2. Date Revised 2022-12-29
Further Info :

Pubmed ID

36511278

DOI: Digital Object Identifier

10.1016/j.beem.2022.101701

Related Literature

Article Analysis
・Side Effects of gefitinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.